

Date of the CVA	22/11/2019
-----------------	------------

Section A. PERSONAL DATA

Name and Surname	Julio Juan Gálvez Peralta		
DNI	24191218W	Age	56
Researcher's identification number	Researcher ID	K-6875-2014	
	Scopus Author ID		
	ORCID	orcid.org/0000-0001-6876-3782	

A.1. Current professional situation

Institution	Universidad de Granada		
Dpt. / Centre	Farmacología / Facultad de Farmacia		
Address	Departamento de Farmacología, Facultad de Farmacia, Campus Universitario de Cartuja s/n, 18071, Granada		
Phone	(34) 620826364	Email	jgalvez@ugr.es
Professional category	CATEDRÁTICO DE UNIVERSIDAD	Start date	2010
UNESCO spec. code	320903 - Evaluation of drugs; 320905 - Pharmacognosy; 320990 - Experimental Pharmacology		
Keywords			

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
DOCTOR EN FARMACIA	Universidad de Granada	1990
LICENCIADO EN FARMACIA	Universidad de Granada	1987

A.3. General quality indicators of scientific production

Miembro CIBER-ehd. Miembro Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA). Coordinador del área de Medicina de Precisión del ibs.GRANADA. Índice h: 39.

Section B. SUMMARY OF THE CURRICULUM

Bachelor of Pharmacy from the University of Granada (UGR) in 1986; Doctor of Pharmacy (UGR) in 1990 (cum laude and Doctorate Special Prize). Training Scholarship Research Staff of the Ministry of Education and Science (1987); Assistant Professor L.R.U. (1991); Associate Professor (1995); Full Professor (2010) in the Department of Pharmacology (UGR). Participation in teaching undergraduate and graduate since 1991. Supervisor of 27 Doctorate Thesis, all with the highest rating, eight of them with European and/or international mention. Three stays at research centers: 1) Biologie und Laboratorium of Farmaceutische Phytopharmacologie (KU Leuven, Belgium), led by Prof. Joseph Lemli (1989); 2) Department of Pharmacology and Therapeutics, University of Malaga, led by Prof. Felipe Sanchez de la Cuesta (1993); 3) Centre for Adult & Paediatric Gastroenterology, Barts & the London School of Medicine & Dentistry at the University of London (UK), led by Prof. Ian R. Sanderson (2005). Member of the Research group "Pharmacology of Natural Products" at UGR (CTS-164), involved in the evaluation of active compounds on intestinal inflammatory conditions and metabolic syndrome, related to immune response and its impact on intestinal microbiota. Participation in 20 research projects with public funding (11 as main researcher) and 25 projects with private funding (18 as principal investigator). This activity is reflected in 134 manuscripts in the field of Pharmacology, Gastroenterology and Nutrition: 68 with the IF in the first quartile (23 in the first decile) and three patents. Member of CIBER-EHD (ISCIII) and coordinator of the area focused Precision Medicine in the Institute ibs.GRANADA

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

- 1 **Scientific paper.** Diez-Echave P; et al. (18/18). 2020. The prebiotic properties of Hibiscus sabdariffa extract contribute to the beneficial effects in diet-induced obesity in mice Food Research International. 127-108722, pp.1-11. ISSN 1873-7145.
- 2 **Scientific paper.** Rodriguez-Nogales A; et al. (9/9). 2019. Calcium Pyruvate Exerts Beneficial Effects in an Experimental Model of Irritable Bowel Disease Induced by DCA in Rats Nutrients. 11-140, pp.1-12. ISSN 2072-6643.
- 3 **Scientific paper.** Vezza T; et al. (10/10). 2019. The Immunomodulatory Properties of Propyl-Propane Thiosulfonate Contribute to its Intestinal Anti-Inflammatory Effect in Experimental Colitis Molecular Nutrition & Food Research. 63-e1800653, pp.1-12. ISSN 1613-4125.
- 4 **Scientific paper.** Garces V; et al. (11/10). 2018. Bacteria-Carried Iron Oxide Nanoparticles for Treatment of Anemia Bioconjugate Chemistry. 29, pp.1785-1791. ISSN 1043-1802.
- 5 **Scientific paper.** Garrido-Mesa J; et al. (10/10). 2018. Immunomodulatory tetracyclines ameliorate DNBS-colitis: Impact on microRNA expression and microbiota composition. Biochemical Pharmacology. 155, pp.524-536. ISSN 0006-2952.
- 6 **Scientific paper.** Garrido-Mesa J; et al. (12/12). 2018. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution. British Journal of Pharmacology. 175, pp.4353-4370. ISSN 0007-1188.
- 7 **Scientific paper.** Rodriguez-Nogales A; et al. (9/9). 2018. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition Journal of Nutritional Biochemistry. 61, pp.129-139. ISSN 0955-2863.
- 8 **Scientific paper.** Toral M; et al. (14/13). 2018. Lactobacillus fermentum Improves Tacrolimus-Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling Molecular Nutrition and Food Research. 1800033, pp.1-13. ISSN 1613-4125.
- 9 **Scientific paper.** Rodriguez-Nogales A; et al. (10/10). 2018. The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice Frontiers in Pharmacology. 9-468, pp.1-12. ISSN 1663-9812.
- 10 **Scientific paper.** Romero M; et al. (10/9). 2017. Activation of peroxisome proliferator activator receptor α improves endothelial dysfunction and protects kidney in murine lupus Hypertension. 69, pp.641-650. ISSN 0194-911X.
- 11 **Scientific paper.** Herranz-Lopez M; et al. (6/4). 2017. Correlation between the cellular metabolism of quercetin and its glucuronide metabolite and oxidative stress in hypertrophied 3T3-L1 adipocytes 2016 Phytomedicine. 25, pp.25-28. ISSN 0944-7113.
- 12 **Scientific paper.** Rodriguez-Nogales A; et al. (10/10). 2017. Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition Molecular Nutrition & Food Research. 61-11, pp.1-13. ISSN 1613-4125.
- 13 **Scientific paper.** Vezza T; et al. (11/11). 2017. Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation Molecular Nutrition & Food Research. 61-10, pp.1-9. ISSN 1613-4125.
- 14 **Scientific paper.** Fabrega MJ; et al. (8/8). 2017. Intestinal Anti-inflammatory Effects of Outer Membrane Vesicles from Escherichia coli Nissle 1917 in DSS-Experimental Colitis in Mice Frontiers in Microbiology. 8-1274, pp.1-13. ISSN 1664-302X.
- 15 **Scientific paper.** Romero M; et al. (7/5). 2017. Protective vascular effects of quercitrin in acute TNBS-colitis in rats: the role of nitric oxide Food & Function. Royal Society of Chemistry. 8, pp.2702-2711. ISSN 2042-6496.
- 16 **Scientific paper.** Diaz de Cerio E; et al. (8/8). 2017. The hypoglycemic effects of guava leaf (Psidium guajava L.) extract are associated with improving endothelial dysfunction in mice with diet-induced obesity Food Research International. 96, pp.64-71. ISSN 0963-9969.
- 17 **Scientific paper.** Algieri F; et al. (17/17). 2016. Anti-inflammatory activity of hydroalcoholic extracts of Lavandula dentata L. and Lavandula stoechas L. in the trinitrobenzenesulphonic acid model of rat colitis Journal of Ethnopharmacology. 190, pp.142-158. ISSN 0378-8741.
- 18 **Scientific paper.** Romero M; et al. (9/8). 2016. Antihypertensive effects of oleuropein-enriched olive leaf extract in spontaneously hypertensive rats. Food & Function. 7, pp.584-593. ISSN 2042-6496.

- 19 **Scientific paper.** Abiodun OO; et al. (8/8). 2016. Antiinflammatory and immunomodulatory activity of an ethanolic extract from the stem bark of *Terminalia catappa* L. (Combretaceae): in vitro and in vivo evidences *Journal of Ethnopharmacology*. 192, pp.309-319. ISSN 0378-8741.
- 20 **Scientific paper.** Hidalgo-Cantabrana C; et al. (8/8). 2016. Effect of a ropy exopolysaccharide-producing *Bifidobacterium animalis* subsp. *lactis* strain orally administered on DSS-induced colitis mice model *Frontiers in Microbiology*. 7, pp.868. ISSN 1664-302X.
- 21 **Scientific paper.** Rodriguez-Nogales A; et al. (11/11). 2016. Effect of aqueous and particulate silk fibroin in a rat model of experimental colitis *International Journal of Pharmaceutics*. 511, pp.1-9. ISSN 0378-5173.
- 22 **Scientific paper.** Algieri F; et al. (12/12). 2016. Intestinal anti-inflammatory activity of calcium pyruvate in the TNBS model of rat colitis: comparison with ethyl pyruvate.*Biochemical Pharmacology*. USA. 103, pp.53-63. ISSN 0006-2952.
- 23 **Scientific paper.** Rodriguez-Nogales A; et al. (10/9). 2016. Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats *International Journal of Nanomedicine*. 11, pp.5945-5958. ISSN 1178-2013.
- 24 **Scientific paper.** Brihi N; et al. (11/11). 2016. Intestinal anti-inflammatory effects of total alkaloid extract 1 from *Fumaria capreolata* in 2 the DNBS model of mice colitis and intestinal epithelial CMT93 cells.*Phytomedicine*. 23, pp.901-913. ISSN 0944-7113.
- 25 **Scientific paper.** Martin M; et al. (9/4). 2016. Magnetic study on biodistribution and biodegradation of oral magnetic nanostructures in the rat gastrointestinal tract *Nanoscale*. 8, pp.15041-15047. ISSN 2040-3364.
- 26 **Scientific paper.** Garrido-Mesa J; et al. (9/9). 2015. A new therapeutic association to manage relapsing experimental colitis: doxycycline plus *Saccharomyces boulardii*.*Pharmacological Research*. 97, pp.48-63. ISSN 1043-6618.
- 27 **Scientific paper.** Gómez-Guzmán M; et al. (10/9). 2015. Antihypertensive effects of probiotics *Lactobacillus* ssp in spontaneously hypertensive rats.*Molecular Nutrition & Food Research*. 59, pp.2326-2336. ISSN 1613-4125.
- 28 **Scientific paper.** Toral M; et al. (11/10). 2015. Chronic peroxisome proliferator-activated receptor α agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity.*Journal of Hypertension*. 33, pp.1831-1844. ISSN 0263-6352.
- 29 **Scientific paper.** Belda-Rustarazo S; et al. (5/5). 2015. Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors.*International Journal of Clinical Practice*. 69, pp.1268-1274. ISSN 1368-5031.
- 30 **Scientific paper.** Utrilla MP; et al. (9/8). 2015. Pea (*Pisum sativum* L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis.*Molecular Nutrition and Food Research*. 59, pp.807-819. ISSN 1613-4125.
- 31 **Scientific paper.** Rodriguez-Nogales A; et al. (10/10). 2015. The viability of *Lactobacillus fermentum* CECT5716 is not essential to exert intestinal anti-inflammatory properties *Food and Function*. 6, pp.1176-1184. ISSN 2042-6496.
- 32 **Scientific paper.** Gómez-Guzmán M; et al. (13/10). 2014. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.*Hypertension*. 64, pp.330-337. ISSN 0194-911X.
- 33 **Scientific paper.** Algieri F; et al. (15/15). 2014. Intestinal Anti-inflammatory Effects of Oligosaccharides Derived from Lactulose in the Trinitrobenzenesulphonic Acid Model of Rat Colitis.*Journal of Agricultural and Food Chemistry*. 62, pp.4285-4297. ISSN 0021-8561.
- 34 **Scientific paper.** Algieri F; et al. (13/13). 2014. Intestinal anti-Inflammatory activity of the *Serpylli* Herba extract in experimental models of rodent colitis *Journal of Crohn's and Colitis*. 8, pp.775-788. ISSN 1873-9946.
- 35 **Scientific paper.** Lozano-Perez AA; et al. (13/13). 2014. Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats.*International Journal of Nanomedicine*. 9, pp.4507-4520. ISSN 1178-2013.

- 36 **Scientific paper.** Toral M; et al. (11/10). 2014. The probiotic *Lactobacillus coryniformis* CECT5711 reduces vascular pro-oxidant and pro-inflammatory status in obese mice. *Clin Sci (Lond)*. 127, pp.33-45. ISSN 0143-5221.
- 37 **Scientific paper.** Camuesco D; et al. (14/14). 2012. The intestinal anti-inflammatory effect of darsalazine sodium is related to a downregulation in IL-17 production in experimental models of rodent colitis. *British Journal of Pharmacology*. 165, pp.729-740. ISSN 0007-1188.
- 38 **Bibliographic review.** Hidalgo-García L; et al. (4/2). 2018. Can a Conversation Between Mesenchymal Stromal Cells and Macrophages Solve the Crisis in the Inflamed Intestine? *Frontiers in Pharmacology*. 2018-9, pp.179. ISSN 1663-9812.
- 39 **Bibliographic review.** Vezza T; et al. (6/6). 2016. Flavonoids in Inflammatory Bowel Disease: A Review. *Nutrients*. 8, pp.211. ISSN 2072-6643.
- 40 **Bibliographic review.** Garrido-Mesa N; Zarzuelo A; Gálvez J. (3/3). 2013. Minocycline: Far beyond an antibiotic *British Journal of Pharmacology*. 169, pp.337-352. ISSN 0007-1188.
- 41 **Bibliographic review.** Garrido-Mesa N; Zarzuelo A; Gálvez J. (3/3). 2013. What is behind the non-antibiotic properties of minocycline? *Pharmacological Research*. 67, pp.18-30. ISSN 1043-6618.

C.2. Participation in R&D and Innovation projects

- 1 Microbiota asociada a la mucosa en obesidad: una diana terapéutica para el tratamiento y prevención del cáncer colorrectal Instituto de Salud Carlos III. Julio Juan Galvez Peralta. (Universidad de Granada). 01/01/2020-31/12/2022. 129.470 €.
- 2 Implementation of a novel platform to monitor tumour heterogeneity as a crucial determinant for individualized diagnostic and therapeutic outcome Instituto de Salud Carlos III (PIE16/00045). Galvez J. (Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA)). 01/01/2017-31/12/2019. 495.000 €.
- 3 PI-0206-2016, Potencial Terapéutico de Exosomas Derivados de Células Estromales Mesenquimales en Inflamación Intestinal Consejería de Salud. LÍNEA DE PROYECTO DE INVESTIGACIÓN, DESARROLLO E INNOVACIÓN BIOMÉDICA Y EN CIENCIAS DE LA SALUD. Rodríguez-Cabezas ME. (Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA)). 01/01/2017-31/12/2019. 50.000 €.
- 4 Nutracéuticos de 2ª generación de plantas comestibles basados en extractos polifenólicos moduladores del metabolismo energético: Aplicaciones en la prevención de la obesidad Ministerio de Economía y Competitividad (AGL2015-67995-C3-3-R). (Universidad de Granada). 01/01/2016-31/12/2018. 90.000 €.

C.3. Participation in R&D and Innovation contracts

- 1 Colaboración en el proyecto "Investigación, desarrollo e innovación en nuevos alimentos multifuncionales para síndrome metabólico (METASIN) (C-4140) Biosearch S.A., Julio Gálvez Peralta. 21/07/2015-21/04/2019. 135.000 €.
- 2 Estudio de Farmacocinética de una formulación de Letrozol ISM Laboratorios Farmacéuticos Rovi; S.A.. Julio Gálvez Peralta. 01/12/2013-P2Y30D. 195.807 €.
- 3 Evaluación Farmacocinética y de seguridad de Risperidona ISM (C-3866) Laboratorios Farmacéuticos Rovi, S.A.. Antonio Zarzuelo Zurita. 03/07/2013-P1Y10M. 524.457 €.

C.4. Patents

- 1 Galvez J; Rodríguez-Cabezas ME; Baños A. WO2015128516. NUEVOS METODOS PARA LA APLICACION DE UN PRODUCTO PARA LA MODULACION DE LA RESPUESTA INMUNOLOGICA EN HUMANOS 03/09/2015. DOMCA, S.A. (ABONOS NATURALES).
- 2 Sañudo A; Criado R; Rodríguez-Nogales A; Garach A; Olivares M; Galvez J; de la Escalera S; Duarte J; Zarzuelo A; Bañuelos O. EP14384202.9. Probiotic strains having cholesterol absorbing capacity, methods and uses thereof 10/02/2015. Biosearch S.A..
- 3 E. M. Rubio Castillo; M. Gómez García; C. Ortiz Mellet; J. Manuel García Fernández; A. Zarzuelo Zurita; J. J. Gálvez Peralta; R. Duval. ES/P200700675. New caramels with high content in prebiotic oligosaccharides, their preparation and use. Spain. 01/01/2007. CSIC-Universidad de Sevilla-Universidad de Granada-Chirosep.